07:42 AM EDT, 08/15/2024 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Thursday that the European Medicines Agency has validated its marketing authorization application for sebetralstat, an oral plasma kallikrein inhibitor designed for the on-demand treatment of hereditary angioedema.

The application, submitted in July, will next undergo review by the EMA's Committee for Medicinal Products for Human Use through the centralized licensing procedure covering all 27 EU member states, along with the EEA countries of Norway, Iceland, and Liechtenstein, KalVista said.